ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT02203526
Brief Title: Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma

First Submitted : July 29, 2014
First Submitted that Met QC Criteria : July 29, 2014
First Posted : July 30, 2014 (Estimate)

Last Update Submitted that Met QC Criteria : November 2, 2018
Last Update Posted : November 5, 2018